Abbreviation
|
Meaning
|
ACT |
adoptive cellular therapy |
ALL
|
acute lymphoblastic leukemia or acute lymphocytic leukemia
|
AML
|
acute myeloid leukemia
|
ASCO
|
American Society of Clinical Oncology
|
ASH
|
American Society of Hematology
|
ASTCT
|
American Society for Transplantation and Cellular Therapy (formerly ASBMT - American Society of Blood and Marrow Transplantation)
|
ATG
|
anti-thymocyte globulin
|
BMI
|
body mass index
|
BMT
|
blood or bone marrow transplant / transplantation
|
BMT CTN
|
Blood and Marrow Transplant Clinical Trials Network
|
CAR
|
chimeric antigen receptor
|
CI |
confidence interval |
CIBMTR
|
Center for International Blood and Marrow Transplant Research
|
CIDR
|
Cellular Immunotherapy Data Resource
|
CLL
|
chronic lymphocytic leukemia
|
CME
|
continuing medical education
|
CML
|
chronic myeloid leukemia
|
CMS
|
Centers for Medicare and Medicaid Services
|
CMV
|
cytomegalovirus
|
CPI
|
continuous process improvement
|
CRC
|
Clinical Research Coordinator
|
CRF
|
Comprehensive Report Form
|
CRID
|
CIBMTR Research ID (a unique identifier for a patient)
|
CRO
|
contract research organization
|
CRO Services
|
CIBMTR Clinical Research Organization Services, formerly known as the Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI BMT)
|
CV
|
curriculum vitae
|
DBtC
|
Data Back to Centers
|
DHHS
|
Department of Health and Human Services
|
DLI
|
donor leukocyte infusion
|
DNA
|
deoxyribonucleic acid
|
DTI
|
Data Transformation Initiative
|
EHR
|
electronic health record
|
EMR
|
electronic medical record
|
ePRO
|
electronic patient reported outcomes (system used by CIBMTR)
|
FACT
|
Foundation for the Accreditation of Cellular Therapy
|
FDA
|
Food and Drug Administration
|
GCSF
|
granulocyte colony-stimulating factor
|
GI
|
gastrointestinal
|
GVHD
|
graft-versus-host disease
|
HCT
|
hematopoietic cell transplant / transplantation
|
HIV
|
human immunodeficiency virus
|
HLA
|
human leukocyte antigen
|
HR
|
hazard ratio
|
HRSA
|
Health Resources and Services Administration
|
IBMTR
|
International Bone Marrow Transplant Registry
|
ICU
|
intensive care unit
|
IDE
|
investigational device exception
|
IOTN
|
Immuno-Oncology Transplantation Network
|
IND
|
investigational new drug
|
IRB
|
institutional review boards
|
IT
|
Information Technology
|
KIR
|
killer-cell immunoglobulin-like receptor
|
MAC
|
myeloablative conditioning
|
MDS
|
myelodysplastic syndrome
|
MMUD
|
mismatched, unrelated donor
|
MPN
|
myeloproliferative neoplasms
|
MRD
|
minimal residual disease
|
NCCN
|
National Comprehensive Cancer Network
|
NCI
|
National Cancer Institute
|
NHL
|
non-Hodgkin lymphoma
|
NHLBI
|
National Heart, Lung, and Blood Institute
|
NIAID
|
National Institute of Allergy and Infectious Disease
|
NIH
|
National Institutes of Health
|
NK cells
|
natural killer cells
|
PASS |
post-authorization safety study |
PBSC
|
peripheral blood stem cell
|
PCORI
|
Patient-Centered Outcomes Research Institute
|
PI
|
principal investigator
|
PRO
|
patient-reported outcomes
|
PTCTC
|
Pediatric Transplant and Cellular Therapy Consortium
|
QOL |
quality of life |
RCI BMT
|
Resource for Clinical Investigations in Blood and Marrow Transplantation, now known as CIBMTR CRO Services (see above)
|
RFI
|
request for information
|
RIC
|
reduced-intensity conditioning
|
SAA |
severe aplastic anemia |
SCTOD
|
Stem Cell Therapeutic Outcomes Database
|
Tandem Meetings
|
Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
|
TED
|
Transplant Essential Data
|
TKI
|
tyrosine kinase inhibitors
|
UCBT
|
umbilical cord blood transplantation
|
US
|
United States of America
|
URD
|
unrelated donor
|
WC
|
Working Committee
|
WMDA
|
World Marrow Donor Association
|